Does valproic acid induce neuroendocrine differentiation in prostate cancer?

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Rodriguez, Ronald ^a   Sidana, Abhinav ^a   Wang, Muwen ^a,b   Chowdhury, Wasim H ^a   Toubaji, Antoun ^a   Shabbeer, Shabana ^c   Netto, George ^a   Carducci, Michael ^c   Lupold, Shawn E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOGRANIN A; NERVE CELL ADHESION MOLECULE; SYNAPTOPHYSIN; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEUROENDOCRINE SYSTEM; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL DIFFERENTIATION; DRUG EFFECT; DRUG SCREENING; METABOLISM; NEUROSECRETORY CELL; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; STAINING; TUMOR CELL LINE;

ANIMALS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMOGRANIN A; HUMANS; MALE; MICE; MICE, NUDE; NEURAL CELL ADHESION MOLECULES; NEUROENDOCRINE CELLS; PROSTATIC NEOPLASMS; STAINING AND LABELING; SYNAPTOPHYSIN; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78650740368     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/607480     Document Type: Article

References (39)

1. Dokmanovic M., Clarke C., Marks P. A., Histone deacetylase inhibitors: overview and perspectives Molecular Cancer Research 2007 5 10 981 989 (Pubitemid 350080267)
2. Konstantinopoulos P. A., Karamouzis M. V., Papavassiliou A. G., Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond Expert Opinion on Investigational Drugs 2007 16 5 569 571
3. Glaser K. B., HDAC inhibitors: clinical update and mechanism-based potential Biochemical Pharmacology 2007 74 5 659 671
4. Shabbeer S., Kortenhorst M. S. Q., Kachhap S., Galloway N., Rodriguez R., Carducci M. A., Multiple molecular pathways explain the anti-proliferative effect of valproic acid on Prostate cancer cells in vitro and in vivo The Prostate 2007 67 10 1099 1110
5. Xia Q., Sung J., Chowdhury W., Chen C.-L., Hti N., Shabbeer S., Carducci M., Rodriguez R., Chronic administration of valproic acid inhibits Prostate cancer cell growth in vitro and in vivo Cancer Research 2006 66 14 7237 7244
6. di Sant'Agnese P. A., de Mesy Jensen K. L., Churukian C. J., Agarwal M. M., Human prostatic endocrine-paracrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron-specific enolase immunoreactivity and silver stains Archives of Pathology and Laboratory Medicine 1985 109 7 607 612
7. Komiya A., Suzuki H., Imamoto T., Kamiya N., Nihei N., Naya Y., Ichikawa T., Fuse H., Neuroendocrine differentiation in the progression of Prostate cancer International Journal of Urology 2009 16 1 37 44
8. di Sant'Agnese P. A., Neuroendocrine differentiation in carcinoma of the Prostate: diagnostic, prognostic, and therapeutic implications Cancer 1992 70 1 254 268
9. Frigo D. E., McDonnell D. P., Differential effects of Prostate cancer therapeutics on neuroendocrine transdifferentiation Molecular Cancer Therapeutics 2008 7 3 659 669
10. Slovin S. F., Neuroendocrine differentiation in Prostate cancer: a sheep in wolf's clothing? Nature Clinical Practice Urology 2006 3 3 138 144
11. Hirano D., Jike T., Okada Y., Minei S., Sugimoto S., Yamaguchi K., Yoshikawa T., Hachiya T., Yoshida T., Takimoto Y., Immunohistochemical and ultrastructural features of neuroendocrine differentiated carcinomas of the Prostate: an immunoelectron microscopic study Ultrastructural Pathology 2005 29 5 367 375
12. Valentini A., Biancolella M., Amati F., Gravina P., Miano R., Chillemi G., Farcomeni A., Bueno S., Vespasiani G., Desideri A., Federici G., Novelli G., Bernardini S., Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human Prostate carcinoma cell line Drug Metabolism and Disposition 2007 35 6 968 972
13. Adler J. T., Hottinger D. G., Kunnimalaiyaan M., Chen H., Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells Surgery 2008 144 6 956 962
14. Greenblatt D. Y., Vaccaro A. M., Jaskula-Sztul R., Ning L., Haymart M., Kunnimalaiyaan M., Chen H., Valproic acid activates Notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells Oncologist 2007 12 8 942 951
15. Platta C. S., Greenblatt D. Y., Kunnimalaiyaan M., Chen H., Valproic acid induces Notch1 signaling in small cell lung cancer cells Journal of Surgical Research 2008 148 1 31 37
16. Adler J. T., Hottinger D. G., Kunnimalaiyaan M., Chen H., Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors Annals of Surgical Oncology 2009 16 2 481 486
17. Adler J. T., Hottinger D. G., Kunnimalaiyaan M., Chen H., Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride Journal of Surgical Research 2010 159 2 640 644
18. Turnbull D. M., Rawlins M. D., Weightman D., Chadwick D. W., Plasma concentrations of sodium valproate: their clinical value Annals of Neurology 1983 14 1 38 42
19. Zha S., Gage W. R., Sauvageot J., Saria E. A., Putzi M. J., Ewing C. M., Faith D. A., Nelson W. G., de Marzo A. M., Isaacs W. B., Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the Prostate, but not in Prostate carcinoma Cancer Research 2001 61 24 8617 8623
20. Manley S., Mucci N. R., de Marzo A. M., Rubin M. A., Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome the Prostate specialized program of research excellence model American Journal of Pathology 2001 159 3 837 843
21. Faith D. A., Isaacs W. B., Morgan J. D., Fedor H. L., Hicks J. L., Mangold L. A., Walsh P. C., Partin A. W., Platz E. A., Luo J., de Marzo A. M., Trefoil factor 3 overexpression in prostatic carcinoma: prognostic importance using tissue microarrays The Prostate 2004 61 3 215 227
22. de Marzo A. M., Knudsen B., Chan-Tack K., Epstein J. I., E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical Prostatectomy specimens Urology 1999 53 4 707 713
23. Huang J., Wu C., di Sant'Agnese P. A., Yao J. L., Cheng L., Na Y., Function and molecular mechanisms of neuroendocrine cells in Prostate cancer Analytical and Quantitative Cytology and Histology 2007 29 3 128 138
24. Bonkhoff H., Neuroendocrine differentiation in human Prostate cancer. Morphogenesis, proliferation and androgen receptor status Annals of Oncology 2001 12 supplement 2 S141 S144
25. Tamas E. F., Epstein J. I., Prognostic significance of Paneth cell-like neuroendocrine differentiation in adenocarcinoma of the Prostate American Journal of Surgical Pathology 2006 30 8 980 985
26. Shimizu S., Kumagai J., Eishi Y., Uehara T., Kawakami S., Takizawa T., Koike M., Frequency and number of neuroendocrine tumor cells in Prostate cancer: no difference between radical Prostatectomy specimens from patients with and without neoadjuvant hormonal therapy The Prostate 2007 67 6 645 652
27. Yamada Y., Nakamura K., Aoki S., Taki T., Matsubara H., Sai S., Naruse K., Tobiume M., Katsuda R., Zennami K., Honda N., Nakagawa A., Ikeda H., Is neuroendocrine cell differentiation detected using chromogranin A from patients with bone metastatic Prostate cancer a prognostic factor for outcome? Oncology reports. 2006 15 5 1309 1313
28. Ishida E., Nakamura M., Shimada K., Tasaki M., Konishi N., Immunohistochemical analysis of neuroendocrine differentiation in Prostate cancer Pathobiology 2009 76 1 30 38
29. Weichert W., Rske A., Gekeler V., Beckers T., Stephan C., Jung K., Fritzsche F. R., Niesporek S., Denkert C., Dietel M., Kristiansen G., Histone deacetylases 1, 2 and 3 are highly expressed in Prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical Prostatectomy British Journal of Cancer 2008 98 3 604 610
30. Pahlman S., Esscher T., Nilsson K., Expression of -subunit of enolase, neuron-specific enolase, in human non-neuroendocrine tumors and derived cell lines Laboratory Investigation 1986 54 5 554 560
31. Haimoto H., Takahashi Y., Koshikawa T., Nagura H., Kato K., Immunohistochemical localization of -enolase in normal human tissues other than nervous and neuroendocrine tissues Laboratory Investigation 1985 52 3 257 263
32. Angelsen A., Syversen U., Haugen O. A., Stridsberg M., Mjlnerd O. KR., Waldum H. L., Neuroendocrine differentiation in carcinomas of the Prostate: do neuroendocrine serum markers reflect immunohistochemical findings? The Prostate 1997 30 1 1 6
33. Kamiya N., Suzuki H., Kawamura K., Imamoto T., Naya Y., Tochigi N., Kakuta Y., Yamaguchi K., Ishikura H., Ichikawa T., Neuroendocrine differentiation in stage D2 Prostate cancers International Journal of Urology 2008 15 5 423 428
34. Kortenhorst M. S. Q., Isharwal S., van Diest P. J., Chowdhury W. H., Marlow C., Carducci M. A., Rodriguez R., Veltri R. W., Valproic acid causes dose- and time-dependent changes in nuclear structure in Prostate cancer cells in vitro and in vivo Molecular Cancer Therapeutics 2009 8 4 802 808
35. Yu D.-S., Hsieh D.-S., Chang S.-Y., Modulation of Prostate carcinoma cell growth and apoptosis by chromogranin A Journal of Urology 2003 170 5 2031 2035
36. Gong J., Lee J., Akio H., Schlegel P. N., Shen R., Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in Prostate cancer cells Endocrinology 2007 148 9 4489 4499
37. Chen C.-S., Weng S.-C., Tseng P.-H., Lin H.-P., Chen C.-S., Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes Journal of Biological Chemistry 2005 280 46 38879 38887
38. Jensen S. M., Gazdar A. F., Cuttitta F., Russell E. K., Linnoila R. I., A comparison of synaptophysin, chromogranin, and L-dopa decarboxylase as markers for neuroendocrine differentiation in lung cancer cell lines Cancer Research 1990 50 18 6068 6074
39. Takamatsu K., Auerbach B., Gerardy-Schahn R., Eckhardt M., Jaques G., Madry N., Characterization of tumor-associated neural cell adhesion molecule in human serum Cancer Research 1994 54 10 2593 2603 (Pubitemid 24173744)